Trial Title:
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
NCT ID:
NCT06533826
Condition:
Breast Cancer
HER2-low Breast Cancer
Metastatic Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Trastuzumab
Trastuzumab deruxtecan
Conditions: Keywords:
Breast Cancer
HER2-low Breast Cancer
Metastatic Breast Cancer
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Crossover Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Trastuzumab Deruxtecan
Description:
A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.
Arm group label:
Arm A (ADC1 T-DXd HR+)
Arm group label:
Arm G (ADC2 T-DXd HR+)
Arm group label:
Arm H (ADC2 T-DXd HR-)
Arm group label:
Arn B (ADC1 T-DXd HR-)
Other name:
Enhertu
Other name:
am-trastuzumab deruxtecan-nxki
Other name:
T-DXd
Other name:
DS-8201a
Intervention type:
Drug
Intervention name:
Datopotamab Deruxtecan
Description:
A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein)
infusion per protocol.
Arm group label:
Arm C (ADC1 Dato-DXd HR+)
Arm group label:
Arm D (ADC1 Dato-DXd HR-)
Arm group label:
Arm E (ADC2 Dato-DXd HR+)
Arm group label:
Arm F (ADC2 Dato-DXd HR-)
Other name:
Dato-DXd
Other name:
DS-1062
Other name:
DS-1062a
Summary:
The purpose of this study is to test the safety and effectiveness of the sequence of two
investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or
datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment
works in treating HER2-low metastatic breast cancer.
The names of the study drugs involved in this study are:
- Datopotamab deruxtecan (a type of antibody drug conjugate)
- Trastuzumab deruxtecan (a type of antibody drug conjugate)
Detailed description:
This is a multi-institutional, open-label, phase 2 trial assessing the efficacy of
sequential antibody drug conjugate (ADC) treatment with Dato-DXd or T-DXd in participants
with HER2-low locally advanced unresectable or metastatic breast cancer (MBC).
There are two parts to this study, which has a sequential design. Most participants will
enroll in Group 1, which has two different study drugs. A participant will be randomized
to receive one of the two study drugs, and if there is progression of disease on the
study drug that was originally assigned, a participant will crossover to a different arm
in Group 2 and receive the other study drug. Some participants may enroll directly to
Group 2 if they already received the first drug. The goal is to evaluate the
effectiveness of sequential ADC therapy by switching the target of the ADC.
Randomization means participants are placed into a treatment arm by chance. Participants
will be randomized into one of four treatment arms in Group 1:
- Arm A: Trastuzumab deruxtecan in hormone receptor (HR)-positive metastatic breast
cancer (MBC)
- Arm B: Trastuzumab deruxtecan in HR-negative MBC
- Arm C: Datopotamab deruxtecan in HR-positive MBC
- Arm D: Datopotamab deruxtecan in HR-negative MBC
Participants may crossover to one of the below treatment arms in Group 2:
- Arm E: Datopotamab deruxtecan in HR-positive MBC
- Arm F: Datopotamab deruxtecan in HR-negative MBC
- Arm G: Trastuzumab deruxtecan in HR-positive MBC
- Arm H: Trastuzumab deruxtecan in HR-negative MBC
The U.S. Food and Drug Administration (FDA) has not approved Datopotamab deruxtecan as a
treatment for HER2-low metastatic breast cancer.
The U.S. FDA has approved Trastuzumab deruxtecan for previously treated HER2-low
metastatic breast cancer, and for other uses.
The research study procedures include screening for eligibility, study treatment visits,
blood tests, tumor biopsies, questionnaires, echocardiograms, electrocardiograms,
Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, and eye
exams.
Participants will receive study treatment for as long as there is benefit. After the
study treatment ends, participants will be followed approximately every six months
thereafter.
It is expected that about 357 people will take part in this research study.
AstraZeneca is supporting this research study by providing the study drugs and funding.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Participants must have histologically or cytologically confirmed invasive breast
cancer with unresectable locally advanced or metastatic disease. Participants
without pathologic or cytologic confirmation of metastatic disease should have
unequivocal evidence of metastasis from physical examination or radiologic
evaluation; i.e., visible chest wall disease or metastases on imaging meeting
standard radiology criteria (i.e., lymph nodes larger than 1 cm in the short axis
diameter).
- The most recent pathology results will be considered for enrollment according to
local testing of ER, PR and HER2 in a CLIA-certified environment. ER, PR and HER2
status per local testing must be known prior to study registration.
- Participants with any HR status will be allowed on study. All participants must have
history of HER2-low breast cancer (determined in any prior tumor sample), as defined
below. The most recent tumor sample may be either HER2-low or HER2-0:
- HR-positive cohorts: ER and/or PR expression ≥1%
- HR-negative cohorts: ER and PR expression <1%
- All cohorts: The most recent HER2 pathology result must be HER2-0 or HER2-low
(i.e., must not be HER2-positive).
- HER2-0: IHC 0+/ISH- or IHC 0+/ISH untested.
- HER2-low: IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested (note: ISH may be
determined by either fluorescence in situ hybridization [FISH] or dual in situ
hybridization [DISH]).
- Participants must have measurable disease per RECIST 1.1.
- Participants must be willing to undergo research tissue biopsies (at baseline prior
to ADC1, after 3 weeks of treatment with ADC1, at progression on ADC1 or baseline
prior to ADC2, and at progression on ADC2), if tumor is safely accessible.
- Prior endocrine therapy: Participants with HR-positive breast cancer considered to
be candidates for endocrine therapy must have: a) progressed on or within 12 months
of adjuvant endocrine therapy or received at least one line of endocrine therapy in
the metastatic setting, and b) received prior CDK4/6 inhibitor. Prior endocrine
therapy does not require washout.
- Prior chemotherapy: Prior lines of chemotherapy allowed in the metastatic setting
are specified below. Prior topoisomerase I inhibitor therapy is not allowed in any
setting, except as specified below for ADC2 cohorts. Participants may have
discontinued all chemotherapy at least 14 days prior to study treatment initiation.
All toxicities related to prior chemotherapy must have resolved to CTCAE v5.0 grade
1 or lower, unless otherwise specified per protocol, except alopecia (any grade
allowed) and neuropathy (grade 2 or lower allowed).
- ADC1 T-DXd cohorts: Participants must have progressed on 0-1 prior lines in the
metastatic setting.
- ADC1 Dato-DXd cohorts: Participants must have progressed on 0-1 prior lines in
the metastatic setting.
- ADC2 T-DXd cohorts: Participants must have progressed on 1-2 prior lines in the
metastatic setting, including Dato-DXd (single-agent) as the most recent
therapy. Confirmation of documented progressive disease on Dato-DXd
(single-agent) as the most recent therapy is required prior to enrollment. No
other topoisomerase I inhibitor is allowed in the metastatic setting.
- ADC2 Dato-DXd cohorts: Participants must have progressed on 1-2 prior lines in
the metastatic setting, including T-DXd (single-agent) as the most recent
therapy. Confirmation of documented progressive disease on T-DXd (single-agent)
as the most recent therapy is required prior to enrollment. No other
topoisomerase I inhibitor is allowed in the metastatic setting.
- Prior biologic or targeted therapy: Patients must have discontinued all biologic or
targeted therapy (e.g., CDK4/6 inhibitor) at least 14 days prior to study treatment
initiation. All toxicities related to prior biologic or targeted therapy must have
resolved to CTCAE v5.0 grade 1 or lower, unless otherwise specified per protocol.
- Prior investigational agents for treatment of cancer: Investigational agents must
have been discontinued at least 21 days prior to initiation of study therapy. All
toxicities related to prior investigational agents must have resolved to CTCAE v5.0
grade 1 or lower, unless otherwise specified per protocol.
- Prior radiation therapy: Patients may have received prior radiation therapy.
Radiation therapy must be completed at least 14 days prior to the initiation of
study treatment (at least 7 days for SRS), and all toxicities related to prior
radiation therapy must have resolved to CTCAE v5.0 grade 1 or lower, unless
otherwise specified per protocol. A 7-day washout is permitted for palliative
radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.
- Patients with history of treated CNS metastases are eligible, provided the following
criteria are met:
- Disease outside the CNS is present.
- Prior SRS/SRT or WBRT should be completed ≥ 7 days before study treatment
initiation.
- Recovery from acute toxicity associated with the treatment to ≤ CTCAE v5.0
grade 1 or baseline (with the exception of alopecia), with no requirement for
escalating doses of corticosteroids over the past 7 days.
- Patients with new or progressive brain metastases (active brain metastases) or
leptomeningeal disease are eligible if the treating physician determines that
immediate CNS specific treatment is not required and is unlikely to be required
during the first cycle of therapy, there is no requirement for corticosteroids, and
the patient is asymptomatic.
- Participants on bisphosphonates or RANK ligand inhibitors may continue receiving
therapy during study treatment and also may initiate therapy with these agents on
study if clinically indicated.
- The subject is ≥ 18 years old.
- ECOG performance status 0-1 (Karnofsky > 60%).
- Participants must have adequate organ and marrow function within 2 weeks prior to
study treatment initiation as defined below:
- Absolute neutrophil count ≥1,500/mcL
- Platelets ≥ 100,000/mcL
- Hemoglobin ≥ 9.0 g/dl
- INR/PT/aPTT ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy
and PT or aPTT is in therapeutic range of anticoagulant
- Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) (or ≤ 3.0 x
ULN in patients with documented Gilbert's Syndrome)
- AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN or ≤ 5.0 × institutional ULN for
participants with documented liver metastases
- Serum or plasma creatinine ≤ 1.5 × institutional ULN OR creatinine clearance
(as calculated using the Cockcroft-Gault equation) ≥ 30 mL/min/ 1.73m2 for
participants with creatinine levels above institutional ULN.
- Resolution of all toxicities related to prior anticancer therapy to Grade ≤ 1 or
baseline, including toxicities from ADC1 before enrolling to ADC2, unless otherwise
specified per protocol.
- For T-DXd cohorts, baseline LVEF ≥ 50% prior to registration, as measured by
echocardiogram (or multiple-gated acquisition [MUGA] scan if an echocardiogram
cannot be performed or is inconclusive).
- Female subjects of childbearing potential must have a negative serum or urine
pregnancy test within 2 weeks prior to study treatment initiation. Childbearing
potential is defined as participants who have not reached a postmenopausal state (≥
12 continuous months of amenorrhea with no identified cause other than menopause)
and have not undergone surgical sterilization (removal of ovaries and/or uterus).
- Women of childbearing potential (WOCBP) and the female partners of male participants
must agree to use an adequate method of contraception. Contraception is required
starting with the first dose of study medication through 7 months after the last
dose of study medication.
- Males who are sexually active with WOCBP must agree to follow instructions for
method(s) of contraception for the duration of study treatment and 4 months after
the last dose of study treatment.
- The participant must be capable of understanding and complying with the protocol and
willing to sign a written informed consent document.
Exclusion Criteria:
- Concurrent use of any other investigational or study agents that are being used to
treat the underlying malignancy.
- Any prior treatment (including ADC) containing a chemotherapeutic agent targeting
topoisomerase I, except as specified per protocol for ADC2 cohorts.
- Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral
vaccines are not considered attenuated live vaccines) within 30 days prior to the
first exposure to study intervention.
- Clinically significant corneal disease.
- History of severe hypersensitivity reactions to either trastuzumab deruxtecan or
datopotamab deruxtecan or their inactive ingredients.
- History of severe hypersensitivity reactions to other monoclonal antibodies.
- Major surgery within 2 weeks prior to study treatment initiation.
- Uncontrolled, significant intercurrent or recent illness including, but not limited
to, ongoing or active infection, uncontrolled non-malignant systemic disease,
uncontrolled seizures, or psychiatric illness/social situation that would limit
compliance with study requirements in the opinion of the treating investigator.
- History of (non-infectious) pneumonitis/interstitial lung disease that required
steroids or current pneumonitis/interstitial lung disease, or where suspected
ILD/pneumonitis cannot be ruled out by imaging at screening. For ADC2 cohorts, if a
participant experienced G1 pneumonitis/ILD with ADC1 (e.g., treated with steroids)
with complete resolution of radiographic findings and ability to resume ADC1 within
12 weeks of the scheduled interruption without recurrence of ILD, the participant
may enroll to ADC2.
- Lung-specific intercurrent clinically significant illnesses including, but not
limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within 3
months of the study enrollment, severe asthma, severe chronic obstructive pulmonary
disease (COPD), restrictive lung disease, pleural effusion etc.), and any
autoimmune, connective tissue or inflammatory disorders with pulmonary involvement
(i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis etc.), and prior
complete pneumonectomy.
- Corrected QT interval (QTcF) prolongation to > 470 msec (females) or >450 msec
(males).
- Any of the following procedures or conditions in 6 months prior to enrollment:
coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction,
angina pectoris, congestive heart failure (New York Heart Association Functional
Classification Grade ≥2), and stroke.
- Individuals with a history of a second malignancy are ineligible except for the
following circumstances:
- Individuals with a history of other malignancies are eligible if they have been
disease-free for at least 3 years or are deemed by the investigator to be at
low risk for recurrence of that malignancy.
- Individuals with the following cancers that have been diagnosed and treated
within the past 3 years are eligible: cervical/prostate carcinoma in situ,
superficial bladder cancer, non-melanoma cancer of the skin.
- Patients with other cancers diagnosed within the past 3 years and felt to be at
low risk of recurrence should be discussed with the study principal
investigator to determine eligibility.
- Known human immunodeficiency virus (HIV) infection that is not well controlled.
- Known hepatitis B or C virus infection that is active or uncontrolled.
- Active infection, including tuberculosis (clinical evaluation that includes clinical
history, physical examination and radiographic findings, and tuberculosis testing in
line with local practice).
- History or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.
- Women who are pregnant or breastfeeding or planning to become pregnant.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Dana-Farber Cancer Institute
Address:
City:
Boston
Zip:
02215
Country:
United States
Contact:
Last name:
Ana Garrido-Castro, MD
Phone:
617-632-3800
Investigator:
Last name:
Ana Garrido-Castro, MD
Email:
Principal Investigator
Start date:
January 2025
Completion date:
August 1, 2038
Lead sponsor:
Agency:
Ana C Garrido-Castro, MD
Agency class:
Other
Collaborator:
Agency:
AstraZeneca
Agency class:
Industry
Collaborator:
Agency:
Translational Breast Cancer Research Consortium
Agency class:
Other
Source:
Dana-Farber Cancer Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06533826
